Dr Kathryn Kolibaba, MD - Tolero Pharmaceuticals - Medical Monitor

Dr Kathryn Kolibaba

MD

Tolero Pharmaceuticals

Medical Monitor

Vancouver, Washington | United States

Main Specialties: Hematology & Oncology

Additional Specialties: hematologic oncology

ORCID logohttps://orcid.org/0000-0003-1099-4638


Top Author

Dr Kathryn Kolibaba, MD - Tolero Pharmaceuticals - Medical Monitor

Dr Kathryn Kolibaba

MD

Introduction

Born in the Willamette Valley of Oregon, Dr. Kolibaba graduated from Woodburn High School and obtained her BS in Zoology from Colorado State University. She attended Oregon Health Sciences University, earning her MD Magna Cum Laude in 1990. Her residency in Internal Medicine was completed at Yale-New Haven Hospital, where she worked in the laboratory of Dr. Nancy Berliner for her first publication. After serving as Chief Medical Resident at Yale-New-Haven Hospital, Dr. Kolibaba and her family returned to Oregon. She completed a fellowship in Hematology and Medical Oncology at Oregon Health Sciences University, working with Dr. Brian Druker. Dr. Kolibaba joined Compass Oncology in 2000, where she was an active participant in the US Oncology Research Program and Hematology Research Committee throughout her clinical practice.

Primary Affiliation: Tolero Pharmaceuticals - Vancouver, Washington , United States

Specialties:

Additional Specialties:

Research Interests:


View Dr Kathryn Kolibaba’s Resume / CV

Education

Jun 1997
Oregon Health Sciences University
Hematology/Medical Oncology
Jun 1994
Yale-New Haven Hospital
Chief Resident
Jun 1993
Yale-New Haven Hospital
Internal Medicine
Jun 1990
Oregon Health Sciences University
MD
Magna Cum Laude

Experience

Internal Medicine, Oncology, Hematology
Board certified

Publications

24Publications

598Reads

67Profile Views

467PubMed Central Citations

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.

Invest New Drugs 2019 04 22;37(2):297-306. Epub 2018 Aug 22.

University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Dr. SPC 591, Ann Arbor, MI, 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0655-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440937PMC
April 2019
27 Reads
2.920 Impact Factor

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2017 Nov 1;35(31):3538-3546. Epub 2017 Sep 1.

John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.2784
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.2784DOI Listing
November 2017
90 Reads
4 Citations
18.430 Impact Factor

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

Blood 2016 Jan 15;127(1):79-86. Epub 2015 Oct 15.

US Oncology Research, Vancouver, WA; Willamette Valley Cancer Institute and Research Center, Eugene, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-03-634394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705612PMC
January 2016
34 Reads
12 Citations
10.452 Impact Factor

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.

Blood 2015 Apr 18;125(15):2336-43. Epub 2015 Feb 18.

Willamette Valley Cancer Institute and Research Center/US Oncology Research, Springfield, OR;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-08-595934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401348PMC
April 2015
46 Reads
35 Citations
10.452 Impact Factor

Molecular monitoring of response in patients with chronic myeloid leukemia.

Manag Care 2013 Jul;22(7):40, 50-61

Northwest Cancer Specialists, Vancouver, WA 98684, USA.

View Article

Download full-text PDF

Source
July 2013
3 Reads

Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.

Invest New Drugs 2009 Oct 25;27(5):476-81. Epub 2008 Oct 25.

US Oncology Research, Inc., Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-008-9191-7DOI Listing
October 2009
2 Reads
1 Citation
2.920 Impact Factor

Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl.

FEBS Lett 2004 Nov;577(3):555-62

Department of Hematology & Medical Oncology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L592 Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2004.10.054DOI Listing
November 2004
1 Read
7 Citations
3.170 Impact Factor

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

Blood 2000 Nov;96(9):3195-9

Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland, OR 97201, USA.

View Article

Download full-text PDF

Source
November 2000
4 Reads
16 Citations
10.452 Impact Factor

CRKL binding to BCR-ABL and BCR-ABL transformation.

Leuk Lymphoma 1999 Mar;33(1-2):119-26

Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland 97201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428199909093732DOI Listing
March 1999
2 Reads

Protein tyrosine kinases and cancer.

Biochim Biophys Acta 1997 Dec;1333(3):F217-48

Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland 97201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0304-419x(97)00022-xDOI Listing
December 1997
3 Reads
36 Citations

Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.

J Biol Chem 1997 Jun;272(26):16170-5

Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland, Oregon 97201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.272.26.16170DOI Listing
June 1997
3 Reads
9 Citations
4.573 Impact Factor

Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.

Blood 1997 Jan;89(1):297-306

Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland 97201, USA.

View Article

Download full-text PDF

Source
January 1997
3 Reads
8 Citations
10.452 Impact Factor

NB4 cells show bilineage potential and an aberrant pattern of neutrophil secondary granule protein gene expression.

Blood 1994 Jul;84(1):294-302

Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510.

View Article

Download full-text PDF

Source
July 1994
3 Reads
17 Citations
10.452 Impact Factor